Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 18/20 | 0.78 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 16/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29962599 | 1.00 | MAPKAPK5 (0.78) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL16279884 | 0.91 | MAPKAPK2 (0.80) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL30514500 | 0.91 | MAPKAPK2 (0.80) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL15311941 | 0.89 | MAPKAPK2 (0.84) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL16279697 | 0.88 | MAPKAPK5 (0.74) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL30514469 | 0.88 | MAPKAPK5 (0.74) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL30514501 | 0.88 | MAPKAPK5 (0.74) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL16280236 | 0.88 | MAPKAPK5 (0.74) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL29963142 | 0.88 | MAPKAPK5 (0.71) | MAPKAPK5MAPKAPK2MAPK14MAPK1 | |
| SCHEMBL24759310 | 0.88 | MAPKAPK5 (0.71) | MAPKAPK5MAPKAPK2MAPK14MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120430-A | MK2 inhibitors and uses thereof | 新特拉有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 45/4885MAPKAPK2 3/4885MAPK14 152/4885 |
| US-11680056-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 45/4885MAPKAPK2 3/4885MAPK14 152/4885 |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 45/4885MAPKAPK2 3/4885MAPK14 152/4885 |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | MAPKAPK5 69/4885MAPKAPK2 3/4885MAPK14 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.